DK1423391T3 - Pyrrolopyrimidiner som midler til inhibering af cysteinproteaser - Google Patents

Pyrrolopyrimidiner som midler til inhibering af cysteinproteaser

Info

Publication number
DK1423391T3
DK1423391T3 DK02797553T DK02797553T DK1423391T3 DK 1423391 T3 DK1423391 T3 DK 1423391T3 DK 02797553 T DK02797553 T DK 02797553T DK 02797553 T DK02797553 T DK 02797553T DK 1423391 T3 DK1423391 T3 DK 1423391T3
Authority
DK
Denmark
Prior art keywords
pyrrolopyrimidines
agents
cysteine proteases
inhibiting cysteine
inhibiting
Prior art date
Application number
DK02797553T
Other languages
Danish (da)
English (en)
Inventor
Claudia Betschart
Kenji Hayakawa
Osamu Irie
Junichi Sakaki
Genji Iwasaki
Rene Lattmann
Martin Missbach
Naoki Teno
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1423391T3 publication Critical patent/DK1423391T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
DK02797553T 2001-08-30 2002-08-29 Pyrrolopyrimidiner som midler til inhibering af cysteinproteaser DK1423391T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0121033.5A GB0121033D0 (en) 2001-08-30 2001-08-30 Organic compounds

Publications (1)

Publication Number Publication Date
DK1423391T3 true DK1423391T3 (da) 2006-09-25

Family

ID=9921234

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02797553T DK1423391T3 (da) 2001-08-30 2002-08-29 Pyrrolopyrimidiner som midler til inhibering af cysteinproteaser

Country Status (30)

Country Link
US (2) US7452886B2 (ru)
EP (1) EP1423391B8 (ru)
JP (1) JP4629334B2 (ru)
KR (1) KR100695845B1 (ru)
CN (1) CN100372849C (ru)
AR (1) AR036374A1 (ru)
AT (1) ATE326469T1 (ru)
AU (1) AU2002333760B2 (ru)
BR (1) BR0212226A (ru)
CA (1) CA2458684C (ru)
CY (1) CY1105573T1 (ru)
DE (1) DE60211530T2 (ru)
DK (1) DK1423391T3 (ru)
EC (1) ECSP044998A (ru)
ES (1) ES2262888T3 (ru)
GB (1) GB0121033D0 (ru)
HK (1) HK1072254A1 (ru)
HU (1) HUP0401301A3 (ru)
IL (3) IL160367A0 (ru)
MX (1) MXPA04001935A (ru)
MY (1) MY157368A (ru)
NO (1) NO328890B1 (ru)
NZ (1) NZ531343A (ru)
PE (1) PE20030418A1 (ru)
PL (1) PL368280A1 (ru)
PT (1) PT1423391E (ru)
RU (1) RU2331644C2 (ru)
TW (1) TWI297690B (ru)
WO (1) WO2003020721A1 (ru)
ZA (1) ZA200401042B (ru)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0220187D0 (en) 2002-08-30 2002-10-09 Novartis Ag Organic compounds
KR20080103117A (ko) 2002-09-24 2008-11-26 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
PE20050068A1 (es) * 2003-02-06 2005-03-11 Novartis Ag 2-cianopirrolopirimidinas como inhibidores de la catepsina s
GB0304640D0 (en) 2003-02-28 2003-04-02 Novartis Ag Organic compounds
US7498323B2 (en) 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
EP1620106A1 (en) * 2003-04-28 2006-02-01 Novartis AG Pharmaceutical composition comprising a cathepsin s inhibitor and an opioid
EP1797883A3 (en) * 2003-04-28 2007-08-01 Novartis AG Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
JP2006525335A (ja) * 2003-04-30 2006-11-09 エフ　エム　シー　コーポレーション 殺虫性（ジハロプロペニル）フェニルアルキル置換ジヒドロベンゾフラン及びジヒドロベンゾピラン誘導体
WO2005011703A1 (en) * 2003-08-04 2005-02-10 Akzo Nobel N.V. 2-cyano-1,3,5-triazine-4,6-diamine derivatives
CA2579609A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
US20070197549A1 (en) 2004-02-18 2007-08-23 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
US20070197510A1 (en) * 2004-03-10 2007-08-23 Kazuyuki Ohmoto Nitriles and medicinal compositions containing the same as the active ingredient
ES2251292B1 (es) * 2004-04-20 2007-07-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
CN1980934B (zh) 2004-05-03 2011-10-26 詹森药业有限公司 作为选择性雄激素受体调节剂（sarms）的新的吲哚衍生物
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
WO2006022454A1 (ja) 2004-08-27 2006-03-02 Ono Pharmaceutical Co., Ltd 塩基性基を含有する化合物およびその用途
KR100651849B1 (ko) * 2005-02-01 2006-12-01 엘지전자 주식회사 세탁기
CA2617725C (en) * 2005-08-05 2012-04-03 Hybrigenics Sa Novel cysteine protease inhibitors and their therapeutic applications
CA2616479A1 (en) 2005-09-01 2007-03-08 Ares Trading S.A. Treatment of optic neuritis
US7326715B2 (en) 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
AR056720A1 (es) * 2005-10-26 2007-10-17 Smithkline Beecham Corp Compuesto de tiazol substtuido composicion farmaceuticamente que lo comprende y su uso para preparar un medicamento
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
KR101415861B1 (ko) * 2005-12-05 2014-07-04 인사이트 코포레이션 락탐 화합물 및 이를 사용하는 방법
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
JP2010503656A (ja) 2006-09-13 2010-02-04 アストラゼネカ アクチボラグ スピロ−オキサゾリジノン化合物と代謝共役型グルタミン酸受容体ポテンシエーターとしてのその使用
US7932251B2 (en) 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
TW200911803A (en) * 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
AR068921A1 (es) 2007-10-19 2009-12-16 Astrazeneca Ab Derivados heterociclicos de tetrazol y 1,2-4 triazoles, composiciones farmaceuticas que los contienen y usos de los mismos para tratar desordenes neurologicos, gastrointestinales y del dolor,entre otros.
CN104800196A (zh) 2008-06-20 2015-07-29 诺华股份有限公司 用于治疗多发性硬化的儿科组合物
US8026236B2 (en) 2009-01-16 2011-09-27 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
TW201035094A (en) 2009-01-16 2010-10-01 Organon Nv 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
JP5677425B2 (ja) 2009-06-29 2015-02-25 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのピリミジノン
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
CN102892768A (zh) 2009-12-30 2013-01-23 艾科尔公司 被取代的吡咯并氨基嘧啶化合物
EP2523954B1 (en) 2010-01-15 2014-04-16 Merck Sharp & Dohme B.V. 1h-[1,2,3]triazolo[4,5-c]pyridine-4- carbonitrile derivatives as cathepsin s inhibitors
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN103339265B (zh) 2010-10-06 2018-03-30 生物医学研究机构私人基金会 用于乳腺癌转移的诊断、预后和治疗的方法
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR102507287B1 (ko) 2011-09-02 2023-03-07 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
JP6172143B2 (ja) * 2012-04-17 2017-08-02 アステラス製薬株式会社 含窒素二環式芳香族へテロ環化合物
ES2705237T3 (es) 2012-06-06 2019-03-22 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón
BR112015008255B1 (pt) 2012-10-12 2023-02-28 Inbiomotion S.L Métodos in vitro para diagnóstico ou prognóstico de metástase óssea em um indivíduo com câncer de próstata e método para classificar um indivíduo que sofre de câncer de próstata em uma coorte
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
US20160032400A1 (en) 2013-03-15 2016-02-04 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
EP3524698A1 (en) 2013-10-09 2019-08-14 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the prognosis and treatment of cancer metastasis
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
MX2017007381A (es) 2014-12-11 2017-11-06 Inbiomotion Sl Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano.
PE20180129A1 (es) 2015-02-27 2018-01-18 Incyte Corp Sales de inhibidor de pi3k y procesos de preparacion
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2017203468A1 (en) 2016-05-25 2017-11-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
BR112020010192A2 (pt) 2017-11-22 2020-10-13 Inbiomotion S.L. tratamento terapêutico de câncer de mama com base no status de c-maf
KR102054910B1 (ko) * 2017-12-19 2019-12-12 한림제약(주) 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
EP3556760A1 (en) * 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
EP3946332A1 (en) 2019-04-05 2022-02-09 Université de Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
WO2022226166A1 (en) * 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL270922A (ru) * 1960-11-02
CH627919A5 (de) 1977-04-14 1982-02-15 Ciba Geigy Ag Herbizide mittel.
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
DK0682027T3 (da) * 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning
US5683999A (en) * 1995-03-17 1997-11-04 The Dupont Merck Pharmaceutical Company Cyclic urea HIV protease inhibitors
ID24653A (id) * 1997-03-19 2000-07-27 Basf Ag Zat-zat terapi
US6384041B1 (en) * 1998-06-30 2002-05-07 Eli Lilly And Company Bicyclic sPLA2 inhibitors
JP2002526500A (ja) * 1998-09-18 2002-08-20 ビーエーエスエフ アクチェンゲゼルシャフト プロテインキナーゼ阻害剤としてのピロロピリミジン
WO2001042246A2 (en) * 1999-12-10 2001-06-14 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
EP1265897A1 (en) * 2000-03-20 2002-12-18 Axys Pharmaceuticals, Inc. Non-amidine containing protease inhibitors
MXPA02010693A (es) 2000-04-28 2003-03-10 Tanabe Seiyaku Co Compuestos ciclicos.

Also Published As

Publication number Publication date
PE20030418A1 (es) 2003-06-12
ATE326469T1 (de) 2006-06-15
HUP0401301A3 (en) 2008-03-28
KR100695845B1 (ko) 2007-03-20
IL160367A (en) 2009-12-24
AR036374A1 (es) 2004-09-01
WO2003020721A1 (en) 2003-03-13
CA2458684A1 (en) 2003-03-13
AU2002333760B2 (en) 2007-01-04
DE60211530T2 (de) 2006-12-21
IL198643A (en) 2010-12-30
MXPA04001935A (es) 2004-06-15
EP1423391B8 (en) 2007-12-12
CA2458684C (en) 2009-04-07
PT1423391E (pt) 2006-09-29
EP1423391B1 (en) 2006-05-17
NO328890B1 (no) 2010-06-07
MY157368A (en) 2016-06-15
DE60211530D1 (de) 2006-06-22
IL160367A0 (en) 2004-07-25
GB0121033D0 (en) 2001-10-24
RU2004109815A (ru) 2005-10-20
RU2331644C2 (ru) 2008-08-20
NO20041180L (no) 2004-03-19
PL368280A1 (en) 2005-03-21
ZA200401042B (en) 2004-10-25
KR20040029123A (ko) 2004-04-03
NZ531343A (en) 2006-01-27
EP1423391A1 (en) 2004-06-02
US20090054467A1 (en) 2009-02-26
CN100372849C (zh) 2008-03-05
BR0212226A (pt) 2004-08-17
JP2005502683A (ja) 2005-01-27
CY1105573T1 (el) 2010-07-28
US20050054851A1 (en) 2005-03-10
JP4629334B2 (ja) 2011-02-09
HK1072254A1 (en) 2005-08-19
HUP0401301A2 (hu) 2004-10-28
ES2262888T3 (es) 2006-12-01
CN1549817A (zh) 2004-11-24
US7452886B2 (en) 2008-11-18
ECSP044998A (es) 2004-04-28
TWI297690B (en) 2008-06-11

Similar Documents

Publication Publication Date Title
DK1423391T3 (da) Pyrrolopyrimidiner som midler til inhibering af cysteinproteaser
DK1351958T3 (da) Imidazol-5-yl-2-anilinopyrimidiner som midler til inhibering af celleproliferation
DK1666071T3 (da) Præparat til restenoseprofylakse
NO20041887L (no) Benzomidazoler anvendelige som proteinkinase-inhibitorer
NO20033593L (no) Kinazoliner som MMP-13 inhibitorer
DE60238291D1 (de) Wafer-Haltevorrichtung
NO20035775L (no) 3-fluor-pyrrolidiner som anti-diabetesmidler
DE60234125D1 (de) E inhibitoren
DE60237865D1 (de) Wippschalter
PT1370553E (pt) Inibidores de rhoquinase
NO20042955L (no) Substituerte fenylaftalener som estrogene midler
NO20040084L (no) Peptid-baserte forbindelser
DK1383731T3 (da) Biarylforbindelser som serinproteaseinhibitorer
NO20033618D0 (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
NO20035728D0 (no) Pyrrolopyrimidiner som proteinkinaseinhibitorer
DE60206317D1 (de) Umschaltventil
DK1458447T3 (da) Kombination af cytokrom-p450-beroende proteasinhibitorer
DK1347739T3 (da) Tokomponent-tandplejemiddel til reduktion af mundlugte
DK1429607T3 (da) Delta-1-pyrroliner som pesticider
DE50207798D1 (de) Tensidmischungen
DE50201549D1 (de) Rückflussverhinderer
DE60214239D1 (de) Schwinghebel
ATE429431T1 (de) 2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren
ITTO20020789A1 (it) Formulazione solida
NO20033234L (no) Karotenoider som antihypertensjonsmidler